These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 18494806

  • 21. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L, Koenen C, Weng W, Selam JL.
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [Abstract] [Full Text] [Related]

  • 22. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.
    Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G.
    Horm Metab Res; 2004 Mar; 36(3):188-93. PubMed ID: 15057674
    [Abstract] [Full Text] [Related]

  • 23. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
    Ross SA, Zinman B, Campos RV, Strack T, Canadian Lispro Study Group.
    Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
    [Abstract] [Full Text] [Related]

  • 24. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [Abstract] [Full Text] [Related]

  • 25. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
    Mäkelä JK, Schmüser C, Askonen K, Saukkonen T.
    Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
    [Abstract] [Full Text] [Related]

  • 26. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients.
    Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E.
    Diabetes Res Clin Pract; 2004 Oct; 66(1):23-9. PubMed ID: 15364158
    [Abstract] [Full Text] [Related]

  • 27. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF, Zhao LB, Li XY, Wang WQ, Sun SY, Chen YH, Hong J, Su TW, Liu JM, Ning G.
    Chin Med J (Engl); 2007 Oct 05; 120(19):1700-3. PubMed ID: 17935674
    [Abstract] [Full Text] [Related]

  • 28. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
    Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N.
    Diabetes Res Clin Pract; 2004 Nov 05; 66(2):193-201. PubMed ID: 15533587
    [Abstract] [Full Text] [Related]

  • 29. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes.
    Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH.
    Diabetes Res Clin Pract; 2006 Feb 05; 71(2):131-9. PubMed ID: 16054266
    [Abstract] [Full Text] [Related]

  • 30. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug 05; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 31. The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice.
    Shah SN, Litwak L, Haddad J, Chakkarwar PN, Hajjaji I.
    Diabetes Res Clin Pract; 2010 May 05; 88 Suppl 1():S11-6. PubMed ID: 20466163
    [Abstract] [Full Text] [Related]

  • 32. Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study.
    Sharma SK, Joshi SR, Kumar A, Unnikrishnan AG, Hoskote SS, Moharana AK, Chakkarwar PN, Vaz JA, PRESENT Study Group.
    J Assoc Physicians India; 2008 Nov 05; 56():859-63. PubMed ID: 19263683
    [Abstract] [Full Text] [Related]

  • 33. Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study.
    Hsieh SH, Lin JD, Cheng HY, Ho C, Liou MJ.
    Clin Ther; 2006 Sep 05; 28(9):1318-26. PubMed ID: 17062305
    [Abstract] [Full Text] [Related]

  • 34. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
    Kvapil M, Swatko A, Hilberg C, Shestakova M.
    Diabetes Obes Metab; 2006 Jan 05; 8(1):39-48. PubMed ID: 16367881
    [Abstract] [Full Text] [Related]

  • 35. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.
    Diabetes Obes Metab; 2009 Jan 05; 11(1):27-32. PubMed ID: 17941873
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.
    Singh KP, Periyandavar I, Rajadhyaksha GC, Jayaram S, Mishra AB, Kinagi S, Sharma A, Baliga VP.
    J Indian Med Assoc; 2007 Jun 05; 105(6):344, 346, 350. PubMed ID: 18232183
    [Abstract] [Full Text] [Related]

  • 37. Long-term glycaemic control with insulin glargine in Type 2 diabetes.
    Kacerovsky-Bielesz G, Dressler A, Freunscht R.
    Diabetes Res Clin Pract; 2006 Feb 05; 71(2):184-91. PubMed ID: 16112241
    [Abstract] [Full Text] [Related]

  • 38. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.
    Yenigun M, Honka M.
    Int J Clin Pract; 2009 Mar 05; 63(3):425-32. PubMed ID: 19222627
    [Abstract] [Full Text] [Related]

  • 39. Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes.
    Barnett AH, Lange P, Dreyer M, Serdarevic-Pehar M, Exubera Phase 3 Study Group.
    Int J Clin Pract; 2007 Oct 05; 61(10):1614-25. PubMed ID: 17877648
    [Abstract] [Full Text] [Related]

  • 40. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
    Hausmann M, Dellweg S, Osborn C, Heinemann L, Buchwald A, Rosskamp R, Genova P, Heise T.
    Diabetes Obes Metab; 2006 Sep 05; 8(5):574-80. PubMed ID: 16918593
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.